In a new strategy that involved cotreatment with fenofibrate and antisense oligonucleotide-fat specific protein 27 (ASO-Fsp27) to mice fed a high-trans-fat, high-cholesterol, and high-fructose diet for eight weeks, the results showed improvement in several symptoms of NASH/NAFLD, which included inflammation, hepatic steatosis, fibrosis, and oxidative stress. This evidence concerns the gene CIDEC and metabolic dysfunction-associated steatotic liver disease.